Claims for Patent: 5,697,902

Summary for Patent: 5,697,902

Title:	Method for imaging and treating organs and tissues
Abstract:	Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.
Inventor(s):	Goldenberg; Milton David (Short Hills, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	08/456,909
Patent Claims:	1. Method for ablating non-malignant cells or tissue in a patient, the method comprising treating the patient with an antibody or antibody fragment specific to a marker associated with or produced by the cells or tissue to be ablated and which is conjugated to a cytotoxic agent, wherein said non-malignant cells or tissue are selected from the group consisting of ectopic tissue, retained tissue, normal organ tissue and bone marrow. 2. The method of claim 1 wherein the cytotoxic agent is an isotope, drug, toxin, fluorescent dye activated by nonionizing radiation, hormone, autocrine or cytokines. 3. The method of claim 2 wherein the isotope is selected from the group consisting of Iodine-125, Iodine-131, Rhenium-186, Rhenium-188, Silver-111, Platinum-197, Palladium-109, Copper-67, Phosphorus-32, Phosphorus-33, Yttrium-90, Scandium-47, Samarium-153, Lutetium-177, Rhodium-105, Praseodymium-142, Praseodymium-143, Terbium-161, Holmium-166 and Gold-199. 4. The method of claim 2 wherein the cytotoxic agent is selected from the group consisting of taxol, mechlorethamine, cyclophosphamide, melphalan, uracil mustard, chlorambucil, thiotepa, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, methotrexate, fluorouracil, cytarabine, azaribine, mercaptopurine, thioguanine, vinblastine, vincristine, dactinomycin, daunorubicin, doxorubicin, bleomycin, mithramycin, mitomycin, L-asparaginase, cisplatin, hydroxyurea, procarbazine, mitotane, prednisone, hydroxyprogesterone caproate, medroprogesterone acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, testosterone propionate and fluoxymesterone. 5. The method of claim 2, wherein the cell or tissue is pretargeted by injecting the subject with a first composition which comprises biotinylated antibody or fragment, optionally injecting the subject with a clearing composition comprising an agent to clear circulating biotinylated antibody or fragment, and then injecting a second composition which comprises biotin conjugated with isotope. 6. The method of claim 1 wherein the antibody is an Fv, single chain antibody, Fab, Fab', or F(ab').sub.2 fragment or intact antibody. 7. The method of claim 1 wherein the antibody or fragment has a specific immunoreactivity to targeted cells or tissues of at least 60% and a cross-reactivity to other antigens of less than 35%. 8. The method of claim 1 wherein the cell or tissue is pretargeted with a first composition comprising a streptavidin-conjugated antibody, biotinylated antibody used in conjunction with avidin and biotin, bifunctional antibody, antibody-hapten complex, or enzyme-conjugated antibody, wherein the antibody is an antibody or antibody fragment which specifically binds a marker produced by or associated with said cell or tissue, and after the first composition accretes at the targeted tissue or cell, a second composition is administered which activates a therapeutic agent on the first composition or couples a therapeutic agent to the first composition to produce a therapeutic agent. 9. The method of claim 1, wherein said non-malignant cells or tissue are ectopic tissue. 10. The method of claim 9, wherein said ectopic tissue is endometrial tissue. 11. The method of claim 1, wherein said non-malignant cells or tissue are retained tissue. 12. The method of claim 1, wherein said non-malignant cells or tissue are normal organ tissue. 13. The method of claim 12, wherein said normal organ tissue is spleen tissue. 14. The method of claim 1, wherein said non-malignant cells or tissue are bone marrow.

Details for Patent 5,697,902

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2014-12-16